Agios Pharmaceuticals AGIO Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$412.78M— | —— | -$352.09M— | —— | ||
| $5.18M-8.4% | $5.65M-14.6% | $6.62M-22.7% | $8.56M-7.3% | ||
| $52.55M+22.7% | $42.85M-4.3% | $44.77M-9.2% | $49.3M-7.9% | ||
| $6.47M— | —— | $604K-72.6% | $2.21M— | ||
| $5.3M-37.9% | $8.54M-19.3% | $10.58M+24.6% | $8.49M— | ||
| —— | —— | —— | $3.44M+84.4% | ||
| —— | $3.69M-71.2% | $12.82M— | —— | ||
| —— | $5.81M— | —— | —— | ||
| —— | —— | —— | $0— | ||
| $12.43M+7.8% | $11.53M+7.6% | $10.72M+7.3% | $10M+4.8% | ||
| -$16.78M-11.8% | -$15.01M-9.8% | -$13.66M-26.2% | -$10.83M-43.9% | ||
| -$372.98M+4.3% | -$389.84M-31.7% | -$296.06M+4.3% | -$309.48M+24.0% | ||
| $4.32M+156% | $1.69M+68.2% | $1M-79.5% | $4.88M-15.3% | ||
| $641.76M-58.4% | $1.54B+269% | $417.93M-59.5% | $1.03B-25.2% | ||
| $1.03B+26.3% | $818.38M+21.3% | $674.68M-41.1% | $1.15B+38.1% | ||
| $377.18M— | —— | $239.58M-1.5% | $243.26M— | ||
| $8.68M-39.9% | $14.44M+166% | $5.43M+103% | $2.68M— | ||
| $8.68M-39.9% | $14.44M+166% | $5.43M+125% | $2.42M+100% | ||
| —— | -$11.96M— | —— | —— | ||
| —— | $43.15M+2,621% | $1.59M— | $0-100% | ||
| $7.2M-50.3% | $14.49M— | —— | $1.2M+117% | ||
| —— | $3.69M-71.2% | $12.82M— | —— | ||
| -$16.78M-11.8% | -$15.01M-9.8% | -$13.66M-26.2% | -$10.83M-43.9% | ||
| —— | $5.81M— | —— | —— | ||
| $12.43M+7.8% | $11.53M+7.6% | $10.72M+7.3% | $10M+4.8% | ||
| $5.18M-8.4% | $5.65M-14.6% | $6.62M-22.7% | $8.56M-7.3% | ||
| $118K-29.8% | $168K+500% | $28K— | —— | ||
| $1.03B+26.3% | $818.38M+21.3% | $674.68M-41.1% | $1.15B+38.1% | ||
| $8.68M-39.9% | $14.44M+166% | $5.43M+103% | $2.68M-92.8% | ||
| —— | $317K+476% | $55K— | —— | ||
| -$16.78M-11.8% | -$15.01M-9.8% | -$13.66M-26.2% | -$10.83M-43.9% | ||
| —— | $43.15M+2,621% | $1.59M— | —— | ||
| -$377.29M+3.6% | -$391.53M-31.8% | -$297.06M+5.5% | -$314.36M+23.9% | ||
| -$377.29M+3.6% | -$391.53M-31.8% | -$297.06M+5.5% | -$314.36M+23.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Agios Pharmaceuticals's cash flow data come from?
- Every line is extracted from Agios Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.